| Next 10 |
Ad
MGTX Articles MeiraGTx Holdings plc
home / stock / mgtx / mgtx articles
Articles | MeiraGTx Holdings plc (NASDAQ:MGTX)
-
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Dutch Bros Inc. (NYSE:BROS). On May 7, Dutch Bros posted bett...
-
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene the...
-
LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene ther...
-
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson&n...
-
- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-link...
-
LONDON and NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene the...
-
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25...
-
MeiraGTx Holdings plc (NASDAQ: MGTX) shares are trading higher after French pharma giant Sanofi SA (NASDAQ: SNY) made a $30 million&...
-
LONDON and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene ther...
Stock Information
Get MGTX Alerts
News, Short Squeeze, Breakout and More Instantly...
MeiraGTx Holdings plc Company Name:
MGTX Stock Symbol:
NASDAQ Market:
0.53% G/L:
$7.69 Last:
647,005 Volume:
$7.52 Open:
$7.69 Close:
MeiraGTx Holdings plc Website:
Ad
-
Team Inc. (TISI) is expected to report for quarter end 2024-12-31 Chesswood Group Limited (CHWWQ) is expected to report for Q4 2024 J. W. Mays Inc. (MAYS) is expected to report for Q2 2025 Allakos Inc. (ALLK) is expected to report $-0.17 for Q4 2024 Aurora Mobile Limited (JG) is e...
-
2025-02-23 03:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
- RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regu...